The Company will initiate its planned clinical study of BIO 300 Injectable Suspension, subject to Institutional Review Board ...
October 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and ...
AM ET SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value ...
IAM1363, now in a Phase 1/1b study, was designed using Iambic’s molecular superintelligence platform and brought to clinical ...
Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: ...
The investigational AI-driven digital assay demonstrated high concordance with MammaPrint results in the prospective RASTER ...
SCI Corporation (NYSE American: CVM) today announced positive new pre-surgical tumor response and safety analyses from its ...
An accomplished biotechnology executive, Ms. Pussinen brings more than 30 years of global leadership experience spanning ...
While biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same ...
After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, ...
The bispecific T cell engager Imdelltra, when used alongside AstraZeneca’s Imfinzi, extended survival by eight months versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results